Onyx Pharmaceuticals, Inc. (ONXX) Says the Price Isn’t Right

Page 2 of 2

The right price
Of course, nearly any pharmaceutical company that makes cancer drugs could be a potential acquirer for Onyx. The big question is: “What price is right?”

Deutsche Bank analyst Robyn Karnauskas says Onyx is worth $148 per share. Geoffrey Porges at Sanford C. Bernstein puts the price tag at $150 per share, but Porges says that $180 per share isn’t out of the question. The Motley Fool’s own Sean Williams thinks $145 per share is reasonable.

With Onyx stock trading a little over $130 per share right now, any of these prices would make for a decent profit. Despite the huge jump since Friday, the current price for Onyx shares just might still be right for investors.

The article Onyx Says the Price Isn’t Right originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Celgene.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2